Search alternatives:
linear decrease » linear increase (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a large » _ large (Expand Search)
Showing 241 - 260 results of 224,509 for search '(( a ((((mean decrease) OR (a decrease))) OR (linear decrease)) ) OR ( a large decrease ))', query time: 1.95s Refine Results
  1. 241
    DNA damage induces a pan-nuclear decrease in GFP-lamin A mobility.

    DNA damage induces a pan-nuclear decrease in GFP-lamin A mobility. by Robert Mahen (409641)

    Published 2013
    Save to List
    Saved in:
  2. 242
    Scatterplot of increased TSB level with increased Narrowband ratio (A) and decreased Broadband ratio (B).

    Scatterplot of increased TSB level with increased Narrowband ratio (A) and decreased Broadband ratio (B). by Lian Zhang (1235682)

    Published 2017
    Save to List
    Saved in:
  3. 243
    Random forest analysis showing discriminating biomarkers of diet-challenge in their decreasing orders of mean decrease accuracies (MDA).

    Random forest analysis showing discriminating biomarkers of diet-challenge in their decreasing orders of mean decrease accuracies (MDA). by Biswapriya B. Misra (563793)

    Published 2019
    Save to List
    Saved in:
  4. 244
    Addition of <i>precA</i> decreases the sensitivity of <i>rarA ruvB</i> cells to DNA damage.

    Addition of <i>precA</i> decreases the sensitivity of <i>rarA ruvB</i> cells to DNA damage. by Kanika Jain (2884439)

    Published 2021
    “…<p>Sensitivity analysis of <i>rarA</i>, <i>ruvB</i>, and <i>rarA ruvB</i> cells with decreased levels of <i>recA</i> towards various DNA damaging agents.…”
    Save to List
    Saved in:
  5. 245
    Mean change in incidence and diagnoses if testing rates decrease.

    Mean change in incidence and diagnoses if testing rates decrease. by Richard T. Gray (282417)

    Published 2013
    “…<p>Change in incidence (A) and diagnoses (B) if testing rates decrease by 30% and 50% relative to the current testing rate.…”
    Save to List
    Saved in:
  6. 246
    Decrease of the mean number of natural teeth and POPs with age.

    Decrease of the mean number of natural teeth and POPs with age. by Sul-Hee Kim (11873853)

    Published 2021
    “…<p>The number of (A) natural teeth and (B) POPs significantly decreased with age in both males and females (<i>P</i> < 0.001). …”
    Save to List
    Saved in:
  7. 247
    Elevated S100A8 level in BALF is associated with an increase of BALF neutrophils and a decrease of physiological function.

    Elevated S100A8 level in BALF is associated with an increase of BALF neutrophils and a decrease of physiological function. by Do Hyung Kim (739231)

    Published 2015
    Save to List
    Saved in:
  8. 248
    The presence of peripheral parasitemia during pregnancy correlates with decreased plasma ANG-1 levels (<i>P</i> = 0.031, mixed linear model).

    The presence of peripheral parasitemia during pregnancy correlates with decreased plasma ANG-1 levels (<i>P</i> = 0.031, mixed linear model). by Karlee L. Silver (343480)

    Published 2013
    Save to List
    Saved in:
  9. 249
    Large direct shear test system.

    Large direct shear test system. by Changbo Du (14014481)

    Published 2023
    “…Additionally, the cohesion and internal friction angle decrease according to a power function with increasing water content, and non-linearly decrease with the rise of fine particle mass fraction. …”
    Save to List
    Saved in:
  10. 250
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 251
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 252
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 253
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 254
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 255
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 256
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 257
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 258
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 259
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 260
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: